NewAmsterdam Pharma (NAMS) filed an 8-K on November 5, 2025, disclosing Q3 2025 financial results and significant pipeline updates. The company is listed on Nasdaq under NAMS (Ordinary Shares) and NAMSW (Warrants).
Financial Performance (Q3 2025): The company reported a cash position of $756.0 million as of September 30, 2025, which management indicates supports a US commercial launch path. Revenue declined significantly year-over-year to $0.3 million (from $29.1 million in Q3 2024) due to the non-recurrence of a 2024 license milestone. The Net Loss widened to \(\\)(72.0M)\( compared to \)
...